Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Abstract excerpt

We examined the influence of mutations and karyotype on conventional treatment response, specifically hematological improvement in anemia, in primary myelodysplastic syndromes (MDS). Cytogenetic and next generation sequencing (NGS)-derived mutation information was available in 357 patients (median age 74 years; 70% males); the revised international prognostic scoring system risk distribution was very high in 11%,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antimetabolites, Antineoplastic
• Share to Dioxygenases